AMENDMENTS TO THE CLAIMS

In the Claims:

1-97. (Canceled)

98. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim 117 ~~93~~.

99. (Currently Amended) A composition comprising the nucleic acid molecule of claim 117 ~~93~~, and a physiologically acceptable carrier or diluent.

100. (Previously Presented) The composition of claim 99, wherein the composition is a vaccine.

101. (Previously Presented) The composition of claim 99, further comprising an immunostimulatory substance.

102. (Previously Presented) The composition of claim 99, wherein the nucleic acid molecule is a DNA molecule.

103. -107. (Canceled)

108. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim ~~103~~ 118.

109. (Currently Amended) A composition comprising the nucleic acid molecule of claim ~~103~~ 118, and a physiologically acceptable carrier or diluent.

110. (Previously Presented) The composition of claim 109, wherein the composition is a vaccine.

111. (Previously Presented) The composition of claim 109, further comprising an immunostimulatory substance.

112. (Previously Presented) The composition of claim 109, wherein the nucleic acid molecule is a DNA molecule.

113. (Currently Amended) A method of making a protein, the method comprising the steps of:

(a) introducing into a cell an expression vector comprising a nucleic acid molecule according to claims 117 or 118 ~~93 or 103~~;

(b) culturing the transfected cell; and

(c) purifying the expressed protein.

114. (Original) The method of claim 113, wherein the cell is a CHO cell.

115. (Original) The method of claim 113, wherein the cell is cultured in suspension, under serum-free conditions.

116. (Previously Presented) The method of claim 113, wherein the expressed protein is purified by a procedure comprising:
(a) anion exchange chromatography; and
(b) hydrophobic chromatography.

117. (Currently Amended) ~~The~~ An isolated nucleic acid molecule ~~of claim 93,~~ encoding a polypeptide comprising:
(a) an amino acid sequence of SEQ ID NO:3; and
(b) an amino acid sequence of SEQ ID NO:4;
wherein ~~(a) consists of SEQ ID NO:3 and (b) consists of SEQ ID NO:4~~ (a) and (b) are joined by an amino acid linker sequence of no more than 50 amino acids; and wherein said polypeptide does not comprise a HER-2/Neu transmembrane domain.

118. (Currently Amended) ~~The~~ An isolated nucleic acid molecule ~~of claim 103,~~ encoding a polypeptide comprising:
(a) an amino acid sequence of SEQ ID NO:3; and
(b) an amino acid sequence of SEQ ID NO:5;
wherein ~~(a) consists of SEQ ID NO:3 and (b) consists of SEQ ID NO:5~~ (a) and (b) are joined by an amino acid linker sequence of no more than 50 amino acids; and wherein said polypeptide does not comprise a HER-2/Neu transmembrane domain .

119. (Previously Presented) An isolated nucleic acid molecule encoding a polypeptide comprising SEQ ID NO:6.

120. (Previously Presented) An isolated nucleic acid molecule encoding a polypeptide comprising SEQ ID NO:7.

121. (Currently Amended) The nucleic acid molecule of claim 117 ~~93~~, wherein the polypeptide is secreted.

122. -123. (Canceled).

124. (Currently Amended) The nucleic acid molecule of claim 118 ~~103~~ , wherein the polypeptide is secreted.

125. (Previously Presented) The composition of claim 109, comprising an oil-in-water emulsion.

126. (Previously Presented) The composition of claim 125, comprising tocopherol.

127. (Previously Presented) The composition of claim 111, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.

128. (Previously Presented) The composition of claim 111, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.

129. (Previously Presented) The composition of claim 128, comprising tocopherol.

130. (Previously Presented) The composition of claim 109, comprising a CpG-containing oligonucleotide.

131. (Canceled)

132. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim 119 ~~131~~.

133. (Currently Amended) A composition comprising the nucleic acid molecule of claim 119 ~~131~~ and a physiologically acceptable carrier or diluent.

134. (Previously Presented)The composition of claim 133, wherein the composition is a vaccine.

135. (Previously Presented) The composition of claim 133, further comprising an immunostimulatory substance.

136. (Previously Presented) The composition of claim 133, wherein the nucleic acid molecule is a DNA molecule.

137. (Currently Amended) The nucleic acid molecule of claim 119 ~~131~~, wherein the polypeptide is secreted.

138. (Previously Presented) The composition of claim 133, comprising an oil-in-water emulsion.

139. (Previously Presented) The composition of claim 135, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.

140. (Previously Presented) The composition of claim 133, further comprising a CpG-containing oligonucleotide.

141. (Canceled)

142. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim 120 ~~141~~.

143. (Currently Amended) A composition comprising the nucleic acid molecule of claim 120 ~~141~~ and a physiologically acceptable carrier or diluent.

144. (Previously Presented)The composition of claim 143, wherein the composition is a vaccine.

145. (Previously Presented) The composition of claim 143, further comprising an immunostimulatory substance.

146. (Previously Presented) The composition of claim 143, wherein the nucleic acid molecule is a DNA molecule.

147. (Currently Amended) The nucleic acid molecule of claim 120 ~~141~~, wherein the polypeptide is secreted.

148. (Previously Presented) The composition of claim 143, comprising an oil-in-water emulsion.

149. (Previously Presented) The composition of claim 145, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.

150.(Previously Presented) The composition of claim 143, further comprising a CpG-containing oligonucleotide.

151. (Currently Amended) A method of making a protein, the method comprising the steps of:

(a) introducing into a cell an expression vector comprising a nucleic acid molecule according to claim 119 or 120 ~~131 or claim 141~~;

(b) culturing the transfected cell; and

(c) purifying the expressed protein.

152. (Previously Presented) The method of claim 151, wherein the cell is a CHO cell.

153. (Previously Presented) The method of claim 151, wherein the cell is cultured in suspension, under serum-free conditions.

154. (Previously Presented) The method of claim 151, wherein the expressed protein is purified by a procedure comprising:
(a) anion exchange chromatography; and
(b) hydrophobic chromatography.

155. (Previously Presented) The composition of claim 99, comprising an oil-in-water emulsion.

156. (Previously Presented) The composition of claim 101, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.

157. (Previously Presented) The composition of claim 99, further comprising a CpG-containing oligonucleotide.

158. (New) The composition of claim 155, comprising tocopherol.

159. (New) The composition of claim 101, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.

160. (New) The composition of claim 159, comprising tocopherol.

161. (New) The composition of claim 138, comprising tocopherol.

162. (New) The composition of claim 139, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.

163. (New) The composition of claim 162, comprising tocopherol.

164. (New) The composition of claim 148, comprising tocopherol.

165. (New) The composition of claim 149, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.

166. (New) The composition of claim 165, comprising tocopherol.